DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
- PMID: 38852020
- DOI: 10.1016/j.metabol.2024.155931
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Abstract
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction-associated steatotic liver disease and metabolism dysfunction-associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest None of the Task Force members received monetary renumeration for their contributions to the creation or writing of this consensus document. See the Supplementary Appendix for full declarations of competing interests for each author.
Similar articles
-
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.J Diabetes Complications. 2022 Feb;36(2):108101. doi: 10.1016/j.jdiacomp.2021.108101. Epub 2021 Dec 7. J Diabetes Complications. 2022. PMID: 34922811 Free PMC article. Review.
-
Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease.Am J Manag Care. 2024 Dec;30(10 Suppl):S189-S196. doi: 10.37765/ajmc.2024.89671. Am J Manag Care. 2024. PMID: 39705195 Review.
-
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39086662 Free PMC article. Review.
-
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.J Diabetes Complications. 2023 Feb;37(2):108389. doi: 10.1016/j.jdiacomp.2022.108389. Epub 2023 Jan 3. J Diabetes Complications. 2023. PMID: 36669322 Review.
-
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Obes Facts. 2024;17(4):374-444. doi: 10.1159/000539371. Epub 2024 Jun 7. Obes Facts. 2024. PMID: 38852583 Free PMC article.
Cited by
-
Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group.Diabetes Metab Res Rev. 2025 Jul;41(5):e70059. doi: 10.1002/dmrr.70059. Diabetes Metab Res Rev. 2025. PMID: 40497316 Free PMC article. Review.
-
Guardians of the sea: molecular and biochemical adaptations in sharks and whales for atherosclerosis resistance and their potential in human cardioprotection.Diabetol Metab Syndr. 2025 Jul 25;17(1):293. doi: 10.1186/s13098-025-01868-5. Diabetol Metab Syndr. 2025. PMID: 40713828 Free PMC article. Review.
-
A decrease in Flavonifractor plautii and its product, phytosphingosine, predisposes individuals with phlegm-dampness constitution to metabolic disorders.Cell Discov. 2025 Mar 17;11(1):25. doi: 10.1038/s41421-025-00789-x. Cell Discov. 2025. PMID: 40097405 Free PMC article.
-
A holistic approach to managing cardio-kidney metabolic syndrome: insights and recommendations from the Italian perspective.Front Cardiovasc Med. 2025 Apr 8;12:1583702. doi: 10.3389/fcvm.2025.1583702. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40264513 Free PMC article.
-
Cardiovascular-Kidney-Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?J Clin Med. 2025 Apr 19;14(8):2833. doi: 10.3390/jcm14082833. J Clin Med. 2025. PMID: 40283662 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous